Pradžia › Trigubai neigiamas krūties vėžys › Nevada
Trigubai neigiamas krūties vėžys klinikiniai tyrimai Nevada
6 tyrimai dėl Trigubai neigiamas krūties vėžys ieško dalyvių vietose Nevada.
Miestai Nevada
Oficialus tyrimo tekstas (anglų kalba)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Optum Care Cancer Center ( Site 9535), Las Vegas
- Comprehensive Cancer Centers of Nevada - Peak ( Site 0047), Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas
- Renown Regional Medical Center ( Site 0005), Reno
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06841354Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-09-03 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07029399A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-29 · NCT05377996Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.